FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Rev. 2-32) PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO. 760-137 CON	SERIAL NO. 10 63
APPLICANT Peavey, T.	'
FILING DATE Herewith	GROUP 3731 (Anticipated)

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
LB	2,904,045	09/15/59	Owings			·
LB	3,310,048	03/21/67	Ewing			
LB	3,998,222	12/21/76	Shihata			
LB	4,092,983	06/06/78	Slivenko			
LB	4,108,174	08/22/78	Slivenko			
LB	5,169,385	12/08/92	Tumbull			
LB	5,637,088	06/10/97	Wenner, et al.			<u> </u>
LB	5,741,228	04/21/98	Lambrecht, et al			
LB	5,931,801	08/03/99	Burbank et al.			

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSI YES	NO
LB	W0 97/47338	12/18/97	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	/:	aura Bouchelle/	08/29/2006	
EXAMINER DAT		DATE CONSIDERED	00/00/0006	
LB		Treating End Stage Renal Disease: The Health and Business Case for Daily Dialysis © 1999 Aksys Ltd. (7 pages).		
LB		An Innovation in Dialysis Access © 1999, Vasca, Inc. (3 pages).		
LB		A New Approach In Hemodialysis, Biolink Corporation, 1999 (4 pages).		

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication with applicant.